155 related articles for article (PubMed ID: 30648627)
1. Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial.
Livi L; Scotti V; Desideri I; Saieva C; Cecchini S; Francolini G; Becherini C; Delli Paoli C; Visani L; Salvestrini V; De Feo ML; Nori J; Bernini M; Sanchez L; Orzalesi L; Bianchi S; Meattini I
Eur J Cancer; 2019 Feb; 108():100-110. PubMed ID: 30648627
[TBL] [Abstract][Full Text] [Related]
2. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.
Lester JE; Dodwell D; Purohit OP; Gutcher SA; Ellis SP; Thorpe R; Horsman JM; Brown JE; Hannon RA; Coleman RE
Clin Cancer Res; 2008 Oct; 14(19):6336-42. PubMed ID: 18829518
[TBL] [Abstract][Full Text] [Related]
3. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
Goss PE; Hershman DL; Cheung AM; Ingle JN; Khosla S; Stearns V; Chalchal H; Rowland K; Muss HB; Linden HM; Scher J; Pritchard KI; Elliott CR; Badovinac-Crnjevic T; St Louis J; Chapman JA; Shepherd LE
Lancet Oncol; 2014 Apr; 15(4):474-82. PubMed ID: 24636210
[TBL] [Abstract][Full Text] [Related]
4. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
Mamounas EP; Bandos H; Lembersky BC; Jeong JH; Geyer CE; Rastogi P; Fehrenbacher L; Graham ML; Chia SK; Brufsky AM; Walshe JM; Soori GS; Dakhil SR; Seay TE; Wade JL; McCarron EC; Paik S; Swain SM; Wickerham DL; Wolmark N
Lancet Oncol; 2019 Jan; 20(1):88-99. PubMed ID: 30509771
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.
McClung MR; Bolognese MA; Sedarati F; Recker RR; Miller PD
Bone; 2009 Mar; 44(3):418-22. PubMed ID: 18950736
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of monthly ibandronate in men with low bone density.
Orwoll ES; Binkley NC; Lewiecki EM; Gruntmanis U; Fries MA; Dasic G
Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
[TBL] [Abstract][Full Text] [Related]
8. Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial.
Lester JE; Dodwell D; Brown JE; Purohit OP; Gutcher SA; Ellis SP; Thorpe R; Horsman JM; Coleman RE
J Bone Oncol; 2012 Sep; 1(2):57-62. PubMed ID: 26909256
[TBL] [Abstract][Full Text] [Related]
9. Monthly Oral Ibandronate Reduces Bone Loss in Korean Women With Rheumatoid Arthritis and Osteopenia Receiving Long-term Glucocorticoids: A 48-week Double-blinded Randomized Placebo-controlled Investigator-initiated Trial.
Shin K; Park SH; Park W; Baek HJ; Lee YJ; Kang SW; Choe JY; Yoo WH; Park YB; Song JS; Lee SG; Yoo B; Yoo DH; Song YW
Clin Ther; 2017 Feb; 39(2):268-278.e2. PubMed ID: 28161119
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
Gnant M; Pfeiler G; Dubsky PC; Hubalek M; Greil R; Jakesz R; Wette V; Balic M; Haslbauer F; Melbinger E; Bjelic-Radisic V; Artner-Matuschek S; Fitzal F; Marth C; Sevelda P; Mlineritsch B; Steger GG; Manfreda D; Exner R; Egle D; Bergh J; Kainberger F; Talbot S; Warner D; Fesl C; Singer CF;
Lancet; 2015 Aug; 386(9992):433-43. PubMed ID: 26040499
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
Brufsky AM; Bosserman LD; Caradonna RR; Haley BB; Jones CM; Moore HC; Jin L; Warsi GM; Ericson SG; Perez EA
Clin Breast Cancer; 2009 May; 9(2):77-85. PubMed ID: 19433387
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
[TBL] [Abstract][Full Text] [Related]
13. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.
Hakala M; Kröger H; Valleala H; Hienonen-Kempas T; Lehtonen-Veromaa M; Heikkinen J; Tuomiranta T; Hannonen P; Paimela L;
Scand J Rheumatol; 2012 Aug; 41(4):260-6. PubMed ID: 22803768
[TBL] [Abstract][Full Text] [Related]
14. Impact of chemotherapy followed by aromatase inhibitors on bone health of women with ER-positive early breast cancer in real world clinical settings in Greece: Results of the POCHARBI trial conducted by the Hellenic Society of Breast Surgeons.
Markopoulos C; Koukouras D; Venizelos V; Karyda I; Xepapadakis G; Misitzis J; Kalogerakos K; Poulakaki F; Natsiopoulos J; Zobolas V; Savidou C; Antonopoulou Z; Tzoracoleftherakis E
Breast; 2016 Jun; 27():27-34. PubMed ID: 27212697
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates may protect against bone loss in postmenopausal women with early breast cancer receiving adjuvant aromatase inhibitor therapy: results from a meta-analysis.
Su G; Xiang Y; He G; Jiang C; Li C; Yan Z; Zhong Y
Arch Med Res; 2014 Oct; 45(7):570-9. PubMed ID: 25450582
[TBL] [Abstract][Full Text] [Related]
16. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
[TBL] [Abstract][Full Text] [Related]
17. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
Cheung AM; Tile L; Cardew S; Pruthi S; Robbins J; Tomlinson G; Kapral MK; Khosla S; Majumdar S; Erlandson M; Scher J; Hu H; Demaras A; Lickley L; Bordeleau L; Elser C; Ingle J; Richardson H; Goss PE
Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
[TBL] [Abstract][Full Text] [Related]
18. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
[TBL] [Abstract][Full Text] [Related]
20. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
van Bodegraven AA; Bravenboer N; Witte BI; Dijkstra G; van der Woude CJ; Stokkers PC; Russel MG; Oldenburg B; Pierik M; Roos JC; van Hogezand RA; Dik VK; Oostlander AE; Netelenbos JC; van de Langerijt L; Hommes DW; Lips P;
Gut; 2014 Sep; 63(9):1424-30. PubMed ID: 24146170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]